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Background: Generation of tolerogenic dendritic cells (TolDCs) for therapy is challenging due to its implications for
the design of protocols suitable for clinical applications, which means not only using safe products, but also
working at defining specific biomarkers for TolDCs identification, developing shorter DCs differentiation methods
and obtaining TolDCs with a stable phenotype. We describe here, a short-term protocol for TolDCs generation,
which are characterized in terms of phenotypic markers, cytokines secretion profile, CD4+ T cell-stimulatory ability
and migratory capacity.
Methods: TolDCs from healthy donors were generated by modulation with dexamethasone plus monophosphoryl
lipid A (MPLA-tDCs). We performed an analysis of MPLA-tDCs in terms of yield, viability, morphology, phenotypic
markers, cytokines secretion profile, stability, allogeneic and antigen-specific CD4+ T-cell stimulatory ability and
migration capacity.
Results: After a 5-day culture, MPLA-tDCs displayed reduced expression of costimulatory and maturation molecules
together to an anti-inflammatory cytokines secretion profile, being able to maintain these tolerogenic features even
after the engagement of CD40 by its cognate ligand. In addition, MPLA-tDCs exhibited reduced capabilities to
stimulate allogeneic and antigen-specific CD4+ T cell proliferation, and induced an anti-inflammatory cytokine
secretion pattern. Among potential tolerogenic markers studied, only TLR-2 was highly expressed in MPLA-tDCs
when compared to mature and immature DCs. Remarkable, like mature DCs, MPLA-tDCs displayed a high CCR7 and
CXCR4 expression, both chemokine receptors involved in migration to secondary lymphoid organs, and even more,
in an in vitro assay they exhibited a high migration response towards CCL19 and CXCL12.
Conclusion: We describe a short-term protocol for TolDC generation, which confers them a stable phenotype and
migratory capacity to lymphoid chemokines, essential features for TolDCs to be used as therapeutics for
autoimmunity and prevention of graft rejection.
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Dendritic cells (DCs) are professional antigen-presenting
cells that play a crucial role in antigen-specific immune
responses and tolerance induction. DCs normally reside
in peripheral tissues, sensing for the presence of either
microbes or endogenous danger signals. Upon recogniz-
ing these signals, DCs undergo a complex process of
maturation, which include changes in morphology, loss
of endocytic receptors, upregulation of antigen presenting
(MHC class I and II), costimulatory (CD80 and CD86) and
functional activator (CD40) molecules, together to in-
creased secretion of cytokines able to polarize T cells [1].
In addition, mature DCs (mDCs) change their expression
pattern of chemokine receptors, acquiring the ability to
migrate to secondary lymphoid organs where they encoun-
ter T cells. It has been largely demonstrated that this traf-
ficking relies on the expression of the chemokine receptor
CCR7, which follows chemotactic gradients of CCL19 and
CCL21 [2], however, new evidence suggests that this
process also requires other chemokine receptor, namely
CXCR4 and its ligand CXCL12 [3]. DCs have been also
implicated in the pathogenesis of multiple autoimmune
diseases, acting as antigen-presenting cells to autoreactive
T cells. However, both immature DCs (iDCs) and tolero-
genic DCs (TolDCs) are involved in the maintenance of
peripheral tolerance. These TolDCs have characteristic
features such as a reduced costimulatory capacity and an
anti-inflammatory cytokine secretion profile [4], and exert
their modulatory activity on autoreactive T cells through
several mechanisms such as clonal deletion or anergy [5].
Moreover, TolDCs are able to promote the differentiation
and proliferation of T cells with regulatory functions [6].
Current efforts for the treatment of autoimmune dis-
eases and other immune processes requiring tolerance
recovery are focused in the development of therapies
aimed at inducing antigen-specific immuneregulation,
with lesser side effects than wide spectrum immunosup-
pressive agents [7]. In this sense, TolDCs capable of
modulating immune responses in an antigen-specific
manner have become a promising therapeutic tool.
TolDCs can be generated ex vivo from peripheral blood
monocytes modulated by different approaches, including
conditioning with pharmacological agents such as vita-
min D3, dexamethasone (Dex) and rapamycin [8-10];
anti-inflammatory cytokines including IL-10 and TGF-β
[5,11]; and genetic modifications such as IL-4 and IL-10
transduction [12,13].
Although numerous investigations have described hu-
man TolDCs mechanisms of action in vitro, up to date
there is only one phase I study describing the adminis-
tration of TolDCs in type 1 diabetes mellitus patients
[14]. Translating laboratory protocols to patients is a
challenging step, since several issues related to thera-
peutic TolDCs generation might be considered, such asi) The use of clinical grade reagents; ii) Cell purity, viabil-
ity, functionality and stability assurance once they encoun-
ter a pro-inflammatory environment, iii) Identification of
specific tolerogenic markers for quality control; and
iv) Shorter generation times, among others [15].
The present study was aimed at developing a short-
ened protocol for the generation of human TolDCs
modulated with Dex and activated with monophosphoryl
lipid A (MPLA), a clinical grade analog for lipopolysac-
charide (LPS). A systematic analysis in terms of yield,
viability, morphology, phenotypic markers, cytokines se-
cretion profile, stability, allogeneic and antigen-specific
CD4+ T-cell stimulatory ability and migration capacity
were performed, in order to evaluate the applicability of
these cells for clinical trials in autoimmune diseases.
Methods
Cell isolation
Buffy coats from healthy volunteers were obtained from
the Clinical Hospital’s Blood Bank at Universidad de Chile
upon informed consent forms were read and signed. The
study was approved by the Clinical Hospital’s Ethical Com-
mittee at Universidad de Chile (Santiago, Chile). CD14+
monocytes and CD4+ T cells were obtained by negative
selection with RosetteSep® Human Monocyte Enrichment
Cocktail and RosetteSep® CD4+ Human T Cell Enrich-
ment Cocktail (StemCell Technologies, Vancouver, BC,
Canada), using a density gradient with Ficoll-Paque™ Plus
(GE Healthcare Bio-Sciences Corp, Piscataway, NJ, USA).
Generation of dendritic cells
Monocytes isolated as described above were cultured
(2-4×106 cells/ml) for 5 days in AIM-V serum-free thera-
peutic grade medium (GIBCO BLR, Invitrogen, Grand Is-
land, NY, USA) in the presence of 500 U/mL of 500 U/mL
of recombinant human (rh) GM-CSF and 500 U/mL of
rhIL-4 (eBioscience, San Diego, CA, USA), refreshing with
fresh medium and cytokines on day 3. In order to induce
a tolerogenic profile, Dex (1 μM, Sigma-Aldrich, St. Louis,
CO, USA) was added on day 3, 48 hours before cell har-
vest, generating tDCs. The current Good Manufacture
Practices (cGMP)-grade MPLA (1 μg/ml, Avanti Polar
Lipids Inc, Alabaster, AL, USA) was added on day 4 to ob-
tain mDCs or activated tDCs (MPLA-tDCs). Untreated
cells were used as iDCs controls. On day 5, cells were
harvested and washed twice with PBS, and phenotypic
and functional analyses were performed.
Flow cytometry analysis
The following antibodies were used for cell surface mole-
cules expression analysis: CD11c APC, CD80 FITC, CD83
FITC, CD40 PE, CD86 PE, MHC II (HLA-DR) FITC,
MHC I (HLA-ABC) FITC, CD1a FITC, CD14 FITC, ILT3
PE, PD-L1 PE, TLR-2 PE, CCR5 PE, CCR7 PE, CXCR1
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APC, all from eBioscience; CCR2 PerCP-Cy5.5 from Bio-
Legend (San Diego, CA, USA) and CCR1 PE from R&D
Systems (Minneapolis, MN, USA). Cells were resuspended
in PBS + 10% FBS and incubated with antibodies for
45 minutes, then washed twice with PBS + 3% FBS and
fixed with IC Fixation Buffer (eBioscience). GILZ PE
antibody (eBioscience) was used for intracellular stain-
ing. Cells were fixed, resuspended in Permeabilization
Buffer (eBioscience) and incubated with the antibody for
20 minutes, then washed twice with Permeabilization
Buffer and resuspended in flow cytometry buffer for data
collection. For IFNγ intracellular detection cells were
stimulated with phorbol-12-myristate-13-acetate (PMA)
(Sigma-Aldrich) (50 ng/ml) / ionomycin (Sigma-Aldrich)
(1 μg/ml) and treated with brefeldin A (eBioscience) (1 μl/
ml) 5 hours prior to cell staining. Data were collected on
a FACSCalibur (Beckton Dickinson, San Diego, CA, USA),
and analyzed using WinMDI 2.9 software. Cell death was
measured by Annexin V and 7-AAD staining (eBioscience).
Cytokine production assessment
DCs were harvested on day 5 of culture, washed and
seeded in 96-well U-bottom plates (BD Biosciences, San
Jose, California, USA) at a concentration of 1×105 cells/
100 μl/well in AIM-V medium with or without a stable
human CD40L-expressing NIH-3 T3 murine fibroblast
cell line at a 1:1 ratio for 24 hours. Supernatants were
collected and stored at −80°C and later analyzed for
cytokine quantification through ELISA sandwich assays
using anti-IL-10, anti-IL-12, anti-IL-23, anti-TNFα and
anti-TGFβ1 antibodies (eBioscience).
Allostimulatory assay
To assess alloproliferation, CD4+ T cells from healthy sub-
jects were purified as described above, and labeled with
carboxyfluorescein diacetate succinimidyl ester (CFSE)
(Sigma-Aldrich) at a concentration of 5 μM for 40×106
cells/ml. Allogeneic DCs were washed three times and
seeded in 96-well U-bottom plates (BD Biosciences) (2×105/
200 μl) with CFSE marked CD4+ T cells at a 1:2 DC/T cell
ratio for 6 days in RPMI medium supplemented with 10%
heat-inactivated fetal calf serum at 37°C and 5% CO2. Anti-
human CD3 antibody-coated wells (eBiocience) were used
to stimulate CD4+ T cells as a positive control. CFSE fluo-
rescence dilution on CD4+ T cells was analyzed by flow
cytometry as a measure of cell proliferation.
Antigen-specific proliferation assay
On day 4 of DC generation, tuberculin purified protein
derivative (PPD) (Staten Serum Institute, Copenhagen,
Denmark) (10 μg/ml) or no antigen was added to cells,
which after 4 hours were stimulated with MPLA (1 μg/ml)
to obtain MPLA-tDCs and mDCs. tDCs received Dex asunique stimulus while iDCs did not receive any stimula-
tion. On day 5, (8×104/200 μl) DCs loaded or not with
PPD were co-cultured with autologous CD4+ T cells la-
beled with CFSE at a 1:2 DC/T cell ratio for 6 days. Cell
proliferation was determined by CFSE fluorescence dilu-
tion on CD4+ T cells by flow cytometry.
Chemotaxis assays
DCs migration was assessed in vitro by using a transwell
system (5 μm pore size polycarbonate membrane inserts,
Corning Costar, NY, USA). DCs (1.5×105) were seeded
in the upper chamber, and AIM-V medium alone or
with 250 ng/ml of the chemokines RANTES/CCL5,
SDF-1α/CXCL12 or MIP-3β/CCL19, all from Peprotech
(Rocky Hill, NJ, USA), were added in the lower chamber.
DCs migration was analyzed after a 4-hour incubation
period at 37°C and 5% CO2 by counting DCs on lower
chamber using flow cytometry. DC migration is expressed
as a migration index, which is the result of the ratio be-
tween the cells migrating towards specific chemokines
and cells migrating towards medium alone.
Statistical analyses
One-way ANOVA for repeated measures and Tukey post-
tests analyses were done using Prism 5.01 Graphpad Soft-
ware (San Diego, CA, USA). For chemotaxis assays, paired
t-tests were used for comparisons between different DC
conditions.
Results
Monocytes differentiate to MPLA-tDCs after a 5-day
culture protocol
Our main goal was the development of a short-term
protocol for TolDC generation for using in clinical appli-
cations. MPLA-tDCs were generated from human mono-
cytes through a 5-day protocol instead of the standard
7-day culture duration [4,16,17], using Dex as tolerizing
agent and MPLA as a replacement of LPS for DC activa-
tion, avoiding the toxicity displayed by the last one. tDCs,
iDCs and mDCs were also differentiated under the same
5-day protocol and they were used as controls as de-
scribed in Materials and Methods. To assess the monocyte
differentiation into DCs, the expression of CD11c, CD1a
and CD14 cellular membrane markers was evaluated on
days 0 and 5. Phenotypic analyses revealed that on day 0,
monocytes expressed high levels of their phenotypic mar-
ker CD14 and also expressed CD11c, a marker shared
with DCs, however they did not express the human DC
marker CD1a (Figure 1A). On day 5, all DC groups treated
under different schemes showed high levels of CD11c and
CD1a expression, together with a loss of CD14 expression
(Figure 1A).
When cellular morphology of 5-day generated DCs was
examined, tDCs exhibited a round shape and they were
Figure 1 In a 5-day culture human monocytes differentiate into dendritic cells (DCs) according to lineage markers and cellular
morphology. After 5 days incubation DCs are CD11c + CD1a + and show lower expression of CD14 compared to monocytes. They also exhibit a
typical DC morphology. (A) 5-day monocyte-derived DCs were differentiated under multiple stimulatory conditions: DC maturated with MPLA
(mDCs), DCs conditioned with dexamethasone (tDCs), tDCs activated with MPLA (MPLA-tDCs) or immature DCs left untreated (iDCs). Cells were
stained with CD14, CD11c and CD1a to assess their development towards fully differentiated DCs. Density plots of monocytes (day 0) and DCs
(day 5) after each differentiation scheme are shown. Plots are representative of 5 independent experiments. (B) Cell morphology was evaluated
by light microscopy on each DCs group on day 5. Representative microphotographs are shown. (C) Cell viability percentage on day 5 is
expressed as the percentage of Annexin V and 7-AAD negative cells (mean ± SEM), while DC yield is expressed as a percentage of DCs obtained
on day 5 related to the initial number of monocytes cultured per condition (mean ± SEM) (n = 7).
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Figure 2 (See legend on next page.)
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Figure 2 MPLA-tDCs exhibit a semi-mature surface phenotype and differentially express high levels of TLR-2. DCs generated following a
5-day protocol were treated with dexamethasone 48 hours before cell harvest for tolerance induction (tDCs). MPLA was added 24 hours before
cell collection to obtain mature DC (mDCs) and also to activate tDCs (MPLA-tDCs). Untreated DCs were used as immature controls (iDCs). (A)
After harvesting, DC surface expression levels of costimulatory (CD80 and CD86), antigen presentation (MHC class I and II), maturation (CD83) and
functional activator (CD40) molecules were assessed by flow cytometry, which are shown as representative histograms of each marker (top) and
graphic analyses of MFI measurements determined for every marker and expressed as mean ± SEM (bottom) (n = 33). (B) TLR-2, PD-L1, GILZ and
ILT3 expression on each DC condition was analyzed by flow cytometry to seek for specific tolerogenic DC markers. Representative histograms
(left) and graphic analyses for each molecule assessed from 13 independent experiments are shown and represented as mean ± SEM (* P < 0.05;
** P < 0.01; *** P < 0.001).
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likely, MPLA-tDCs and mDCs showed a more elongated
form and were easily detached by pipetting (Figure 1B).
Regarding DC yield and cellular viability, no significant
variations between all differentiation conditions were de-
tected (Figure 1C).
MPLA-tDCs phenotypic analyses revealed an intermediate
expression level of functional cellular markers and a high
TLR-2 expression
In order to obtain a complete phenotypic characterization
for DCs differentiated with various stimuli, the expression
of costimulatory (CD80 and CD86), antigen presentation
(MHC class I and II), maturation (CD83) and functional ac-
tivator (CD40) molecules was analyzed by flow cytometry
(Figure 2A). Interestingly, both MPLA-tDCs and tDCs
displayed low levels of CD80 and CD86 expression com-
pared to mDCs (p < 0.001). In parallel, MPLA-tDCs showed
higher expression levels of CD80 than tDCs (p < 0.01). Al-
though MPLA-tDCs and tDCs showed a similar CD86
expression to those of iDCs, MPLA-tDCs showed higher
CD80 expression than iDCs (p < 0.01). In addition, MPLA-
tDCs displayed higher MHC class I expression than iDCs
(p < 0.001) and tDCs (p < 0.01) but similar to that of mDCs.
However, for MHC class II, MPLA-tDCs showed expres-
sion levels similar to iDCs and tDCs but lower than mDCs
(p < 0.01). In the same manner, both MPLA-tDCs and tDCs
displayed lower CD83 (p < 0.001 in both cases) and CD40
(p < 0.01 and p < 0.001, respectively) expression levels than
mDCs, and a similar expression of both molecules as iDCs
and between each other. Taken together, this information
suggests that the cellular markers pattern exhibited by tDCs
corresponds to an immature stage of phenotypic differenti-
ation, while those displayed by MPLA-tDCs are rather con-
cordant to a transition between immature and mature
stages. A similar outcome was seen when activating with
LPS (data not shown).
Another important point to be considered in the es-
tablishment of protocols for DC generation in order to
translate them from the laboratory to the clinic is the
identification of specific tolerance molecules to be used
as quality control markers. For this purpose, we evalu-
ated the expression of TLR-2, glucocorticoid induced
leucine zipper protein (GILZ), the programmed deathligand 1 (PD-L1) and immunoglobulin like transcript
(ILT) 3 (Figure 2B), which have been postulated as
TolDC markers [18,19]. Of all tolerance markers tested,
only TLR-2 was significantly increased in both MPLA-
tDCs and tDCs in comparison to iDCs (p < 0.001 and
p < 0.01, respectively) and mDCs (p < 0.001 and p < 0.01,
respectively). Noteworthy, when tDCs were activated
with MPLA they displayed a higher expression level of
TLR-2 (p < 0.05) (Figure 2B). We did not observe dif-
ferences in the expression of GILZ, PD-L1 and ILT3 on
MPLA-tDCs or mDCs, but we detected lower levels
of these molecules on tDCs in comparison with mDCs
(p < 0.001, p < 0.01 and p < 0.01, respectively) (Figure 2B).
MPLA-tDCs produce low levels of pro-inflammatory
cytokines but exhibit a strong IL-10-secreting profile
The evaluation of pro-inflammatory and anti-inflammatory
cytokines secretion patterns allows a more precise charac-
terization of DCs, and also provides important information
about the mechanisms through which they could influence
immunological processes occurring in vivo. As reported by
Harry et al. [17], pro-inflammatory cytokines secreted by
DCs were undetectable unless stimulating with CD40L-
transfected cell lines for 24 hours before supernatants
collection. Thus, in the presence of CD40L stimulation,
MPLA-tDCs, tDCs and iDCs released significantly lower
levels of IL-12 than mDCs (p < 0.001 for all comparisons)
(Figure 3A). Likewise, both MPLA-tDCs and tDCs
produced lesser IL-23 and TNFα than mDCs (p < 0.05;
p < 0.001 for IL-23 and p < 0.01; p < 0.001 for TNFα,
respectively) and iDCs (p < 0.05; p < 0.001 for IL-23 and
p < 0.01; p < 0.001 for TNFα, respectively).
On the contrary, in the absence of CD40L stimulation,
MPLA-tDCs revealed a strong anti-inflammatory profile,
secreting significantly more IL-10 than did either iDCs
(p < 0.05) or mDCs (p < 0.01) (Figure 3B), while tDCs
produced higher IL-10 levels than mDCs (p < 0.05). For
TGFβ1, both MPLA-tDCs and tDCs secreted same
levels as iDCs and mDCs did (Figure 3B). However, in
the presence of CD40L stimulation for 24 hours, MPLA-
tDCs, tDCs and iDCs produced almost 12, 40 and 30
times higher amounts of IL-10 than in the absence of
CD40L stimulation, respectively (p < 0.001 in all com-
parisons) (Figure 3C). Interaction with CD40L slightly
Figure 3 MPLA-tDCs display an anti-inflammatory cytokine secretion profile with major IL-10 production. MPLA-tDCs show a
pro-tolerogenic cytokine secretion profile with high anti-inflammatory cytokines production and reduced pro-inflammatory cytokines secretion.
On day 5, harvested DCs were washed and then incubated for another 24 hours in AIM-V medium alone or co-cultured with the NIH-3 T3 murine
fibroblast cell line transfected with human CD40L at a 1:1 DCs:fibroblasts ratio. Culture supernatants were collected and further analyzed by ELISA
for pro- and anti-inflammatory cytokines detection. Untreated immature DCs (iDCs) as well as MPLA-matured DCs (mDCs) were used as controls.
(A) IL-12, IL-23 and TNFα levels determined for all DC groups upon CD40L stimulation. Levels of these cytokines were undetectable in
supernatants of DCs without CD40L stimulation. (B) IL-10 and TGFβ1 were detected in supernatants of DCs cultured for 24 hours in AIM-V
medium. (C) IL-10 and TGFβ1 were also determined in supernatants of DCs co-incubated with fibroblasts expressing CD40L. Data in A, B and C
correspond to mean ± SEM of 13 independent experiments (* P < 0.05; ** P < 0.01; *** P < 0.001).
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times more elevated in all conditions studied (Figure 3C).
These results suggest that after tDCs are stimulated
with MPLA, cytokine secretion profiles remain unchanged;
moreover, when MPLA-tDCs are subjected to a second ac-
tivation stimulus such as CD40L, they maintain and even
strengthen an IL-10-dominated anti-inflammatory profile.
In order to further validate MPLA-tDC stability, we
evaluated the expression of costimulatory, maturation
and functional activator molecules in differentially stimu-
lated DCs after a strong second activation stimulus with
CD40L-transfected cells. The analysis of cellular markers
in the presence or absence of CD40L stimulus showed that
CD80, CD86, CD83 and CD40 are expressed at similar
levels in both conditions (Results not shown). Thus, the
phenotypic differences observed between all DC groups
studied remained unaltered after CD40 engagement, con-
firming the stability of MPLA-tDCs.MPLA-tDCs modulate allogeneic CD4+ T cells responses
With the purpose to determine the antigen presenting cell
ability of the different DC types, we evaluated their ability
to induce T cell proliferation in co-cultures with allogeneic
CD4+ T lymphocytes. As shown in Figure 4A, MPLA-
tDCs, tDCs and iDCs showed reduced capacity to induce
T cell alloproliferation when compared to mDCs (p < 0.001
for all 3 conditions). The reduced proliferation of CD4+ T
cells achieved by MPLA-tDCs was not caused by the in-
duction of apoptosis, as determined by annexin V and 7-
AAD staining (data not shown). To further characterize
the type of alloreactive response induced, we also analized
intracellular IFNγ expression by CD4+ T cells following
co-cultures with all DC stages. As expected, when MPLA-
tDCs, tDCs or iDCs were used as stimulators, the percent-
age of actively proliferating IFNγ-producing CD4+ T cells
was significantly decreased compared to that induced by
mDCs (p < 0.001 for all comparisons) (Figure 4B).
Figure 4 MPLA-tDCs display reduced capability to stimulate allogeneic CD4+ T cell proliferation and IFNγ production. MPLA-tDCs and
tDCs show decreased allostimulatory capacity compared to MPLA-matured DCs and similar to iDCs. (A) Alloproliferative response induced by
MPLA-tDCs and tDCs was assessed by co-culturing with allogeneic CD4+ T cells stained with CFSE at a 1:2 DC/T cell ratio for 6 days, and
proliferation was determined by CFSE dilution through flow cytometry. CD4+ T cells incubated alone or treated with anti-CD3 (OKT3 clone) were
used as controls. Representative flow cytometry plots (left) and graphic analysis of DC allostimulatory capacity for all conditions expressed as
percentage of CD4+ CFSElow T cells from 7 independent experiments (right) are shown. (B) Production of IFNγ by allogeneic CD4+ T cells was
measured on day 6 of culture through intracellular staining after stimulation of cells with PMA/ionomycin for 5 hours and analyzed by flow
cytometry. Representative flow cytometry plots (left) and graphic analysis of percentage of IFNγ producing CD4+ CFSElow T cells from 4
independent experiments (right) are shown. Horizontal lines represent median values (*** P < 0.001).
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proliferation
We next investigated whether the MPLA-tDC-induced
low CD4+ T cell proliferation observed in allogeneic cul-
tures was reproduced in an antigen-specific assay, by co-
culturing PPD-loaded DCs with autologous CD4+ T cells
stained with CFSE. Unloaded DCs were also co-cultured
with T cells as controls. As shown in Figure 5A, antigen-
specific CD4+ T cell proliferation response was signifi-
cantly reduced by PPD-loaded MPLA-tDCs, analogously
to tDCs and iDCs, when compared to that displayed by
PPD-loaded mDCs (p < 0.001 for all conditions). Further-
more, when CD4+ T cells were co-cultured with MPLA-
tDCs, tDCs or iDCs, the percentage of actively proliferat-
ing IFNγ-producing CD4+ T cells was significantly re-
duced compared with that exhibited by mDCs (p < 0.01
for all comparisons) (Figure 5B). In contrast, when IL-10in culture supernatants was assessed, CD4+ T cells co-
cultured with MPLA-tDCs produced higher levels than
those secreted by CD4+ T cells cultured with tDCs or
iDCs (p < 0.05 for all comparisons) (Figure 5C).
Taken together, all these results suggest that MPLA-
tDCs can modulate both allogeneic and antigen-specific
CD4+ T cell responses, reducing their proliferation and
polarizing their proinflammatory cytokine profile into an
anti-inflammatory one.Activation of tDCs with MPLA confers them the ability to
migrate towards lymphoid tissue-homing chemokines
To exert an effective antigen-specific immunoregulatory
response in vivo, TolDCs should be capable to migrate to
secondary lymphoid tissues where they will present anti-
gens to T cells under a pro-tolerogenic context. However,
Figure 5 MPLA-tDCs modulate CD4+ T cell responses in an antigen-specific manner. CD4+ T cells co-cultured with autologous PPD-loaded
MPLA-tDCs exhibited impaired proliferative response together to a reduced IFNγ production and high IL-10 secretion. (A) Antigen-specific T cell
responses were assessed by co-culturing DCs with autologous CD4+ T cells stained with CFSE at a 1:2 DC/T cell ratio for 6 days, and proliferation
was determined by CFSE dilution by flow cytometry. CD4+ T cells incubated alone and CD4+ T cells treated with anti-CD3 (OKT) were used as
controls. Representative flow cytometry plots (left) and graphic analysis of DC antigen-specific stimulatory ability for all conditions expressed as
number of CD4+ CFSElow T cells for 6 independent experiments (right) are shown. (B) Production of IFNγ by autologous T cells was measured
on day 6 of culture through intracellular staining after stimulation of cells with PMA/ionomycin for 5 hours and analyzed by flow cytometry.
Representative flow cytometry plots (right) and graphic analysis of the number of IFNγ producing CD4+ CFSElow T cells from 6 independent
experiments are shown. In A and B horizontal lines represent median values (* P < 0.05; ** P < 0.01; *** P < 0.001). (C) IL-10 secretion levels from
DC/T cell culture supernatants were measured using ELISA. Results are represented as the mean ± SEM of 5 independent experiments (* P < 0.05).
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to express low CCR7 levels, the most relevant lymphoid
tissue-homing chemokine receptor [2]. In addition, Dex-
induced TolDCs are unable to migrate in vitro towards a
CCL19 gradient, the specific ligand of CCR7, unless they
become activated by LPS or an analog as MPLA [20].As depicted in Figure 6A, MPLA-tDCs and mDCs
displayed a higher CCR7 and CXCR4 surface expression,
both chemokine receptors involved in migratory response
towards secondary lymphoid organs [3], when compared
to tDCs (p < 0.05 and p < 0.001 for CCR7; p < 0.01 in
both comparisons for CXCR4, respectively) and to iDCs
Figure 6 (See legend on next page.)
García-González et al. Journal of Translational Medicine 2013, 11:128 Page 10 of 15
http://www.translational-medicine.com/content/11/1/128
(See figure on previous page.)
Figure 6 MPLA-activated tDCs acquire secondary lymphoid homing capacity in response to CCR7 and CXCR4 ligands compared to
non-activated tDCs. MPLA activation of tDCs induces upregulation of migratory receptors CCR7 and CXCR4 and enhances chemotactic
responsiveness to their ligands CCL19 and CXCL12. MPLA was added 24 hours before cell harvest to induce tDCs activation, generating
MPLA-tDCs. After cell collection on day 5, DCs chemokine receptors expression profile was evaluated by flow cytometry together with their
migratory response to relevant chemokines. tDCs without MPLA activation, mature (mDCs) and immature controls (iDCs) were also studied.
(A) Representative density plots for each chemokine among CD11c + DCs (left). Data are also shown as the mean ± SD percentage of CD11c +
DCs expressing the respective receptor analyzed from 10 independent experiments (right). (B) DC migratory capacity in response to 250 ng/ml of
CCL19, CXCL12 or CCL5, or to medium alone, was assessed through a transwell assay. DC migration for each chemokine is expressed as the
mean ± SD of migration index (Migrating DCs towards chemokine/Migrating DCs towards medium) determined in duplicates in 6 independent
experiments (* P < 0.05; ** P < 0.01; *** P < 0.001).
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isons for CXCR4, respectively). Expression analyses for
chemokine receptors associated to migration towards in-
flamed tissues, such as CCR1, CCR2 and CCR5, revealed a
down-regulation of these molecules on MPLA-tDCs com-
pared to tDCs (p < 0.001; p < 0.01 and p < 0.01, respec-
tively) (Figure 6A). Moreover, tDCs showed the highest
expression for all 3 chemokine receptors, even more ele-
vated than iDCs, a feature that was completely reverted
after activation with MPLA. The evaluation of CXCR1
and CXCR2 expression did not show significant differ-
ences between all DC groups studied (data not shown).
In order to define whether the higher CCR7 and CXCR4
and lower CCR5 expression exhibited by MPLA-tDCs
have functional relevance, an in vitro migration assay was
performed using the ligands of these chemokine receptors:
CCL19, CXCL12 and CCL5, respectively (Figure 6B). In
agreement with the chemokine receptors expression pat-
tern, iDCs and tDCs exhibited a lower migration index in
comparison to mDCs in response to CCL19 and CXCL12
(p < 0.001 in both cases –iDCs and tDCs– for CCL19 and
CXCL12); however, this tendency was reverted after acti-
vation with MPLA (p < 0.01 for CCL19 and p < 0.05 for
CXCL12 compared to tDCs) (Figure 6B). In contrast,
MPLA-tDCs showed a lower migratory response towards
CCL5 than tDCs (p < 0.01), similar to iDCs and mDCs.
These results allow us to conclude that 5-day generated
tDCs gain lymphoid tissue-homing capacity in response
to CCR7 and CXCR4 ligands only after receiving a MPLA
activation stimulus.
Discussion
TolDCs have become a promising tool to be used as
therapy in autoimmune diseases and transplantation. The
present study reports the development of an alternative
protocol for TolDCs generation for clinical purposes, using
Dex as immunomodulator and the non-toxic LPS deriva-
tive MPLA as TolDCs activator. Dex is known to be an
anti-inflammatory and immunosuppressive agent, which
has been widely used to treat several autoimmune disor-
ders and prevent graft rejection [21]. In addition to other
pharmacological agents, Dex has been extensively studied
for TolDCs generation in rodents [22] as well as in humans[23]. An interesting approach has been the generation
of “alternatively activated” TolDCs, which after receiving
a modulating Dex plus vitamin D3 stimulus are acti-
vated with LPS [20,24]. These TolDCs have shown to be a
transitory stage between iDCs and mDCs, with a stable
phenotype and capable to increase allograft survival and
reduce severity of collagen-induced arthritis [25,26]. Mean-
while, MPLA, a non-toxic synthetic LPS analog that retains
the ability to activate a variety of cells through TLR-4 sig-
naling, exhibits a potent immune-stimulatory capacity [27].
Even more, it has been shown that LPS and MPLA stimu-
lation display similar bioactivity in the murine macrophage
cell line RAW 264.7, inducing equivalent production of
nitric oxide, TNFα and IL-6 [28]. Since MPLA has shown
to be a safe, well-tolerated and effective enhancer of im-
mune responses in animals, it has been considered useful
as adjuvant for several human vaccines [27-29].
In this study, we aimed to develop a shorter DC-
generation protocol instead of the standard 7-day proto-
cols [4,16,17]. We addressed the efficacy of the procedure
by analyzing specific DC and monocyte markers at the
initial and at the final cellular differentiation stages. Inter-
estingly, after 5 days of culture, monocyte-derived cells
acquired a characteristic DC phenotype defined by low
CD14 and high CD11c and CD1a expression, the latter
completely absent in monocytes as established by others
[30]. It is noteworthy that tDCs showed a decreased CD1a
expression and exhibited moderate levels of CD14, sug-
gesting a lesser extent of differentiation, probably due to
Dex effects. Even more, when Dex was added earlier dur-
ing the protocol, monocytes fail to differentiate (data not
shown), which is in agreement with data reported by
Woltman et al. [23]. The effect of Dex on DC differenti-
ation was reversed when tDCs were activated with MPLA.
Even though treatment with Dex can affect tDCs differ-
entiation, there were no effects on cell viability or yield of
tDCs and MPLA-tDCs when compared to iDCs and
mDCs. These results differ from other studies that show
reduced DC viability and yield when treated with Dex [4].
Likely, differences seen in our results in comparison with
others may be explained by variations in the experimental
procedures such as maturation stimuli, Dex and cytokines
concentration, together to the protocol duration.
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phenotype characterized by reduced expression of cos-
timulatory (CD80 and CD86), antigen presentation (MHC
class I and II), maturation (CD83) and functional activator
(CD40) molecules, which could lead to an alternative anti-
gen presentation and costimulation [1,21]. These features
together with an anti-inflammatory cytokine secretion pro-
file give TolDCs the ability to establish tolerance through
the induction of anergy or deletion of auto-reactive T cells,
and also through the promotion of regulatory T cell re-
sponses [31]. In our study, MPLA-tDCs exhibited similar
expression levels of costimulatory, antigen presentation,
maturation and functional activator molecules as tDCs, in-
dicating that even after receiving an activating stimulus,
DCs with a tolerogenic rather than a mature phenotype
were obtained.
When considering TolDCs for therapy, the rapid and
easy identification of specific markers of tolerogenicity is
essential for using them as quality control indicators
during TolDCs generation. In this sense, very few mole-
cules have been described to be exclusively expressed on
TolDCs, and participating in DC regulatory mecha-
nisms. Thus, the immunoglobulin like transcript inhibi-
tory receptor family members, ILT3 and ILT4, have shown
to be upregulated in DCs with regulatory properties and
have been associated with TolDCs capacity for inducing
anergy in T cells [32]; PD-L1 has been reported to be
related with tolerance induction [33]; GILZ has been in-
volved in inducing a tolerogenic/regulatory phenotype
when upregulated in DCs [34], while TLR-2 has been
shown to be upregulated in TolDCs and can also be indu-
cible by glucocorticoids [19,35]. In the present study, only
TLR-2 expression was shown to be upregulated in tDCs,
but more important, when these DCs were activated with
MPLA they increased the expression level of TLR-2, sug-
gesting that can be used as a quality control marker for
the generation of MPLA-tDCs.
Cytokines secreted by DCs during T cell priming play
an important role in the subsequent differentiation of ef-
fector T cells [36]. MPLA-tDCs generated following our
5-day protocol exhibited an anti-inflammatory cytokine
secretion profile, characterized by a low production of
IL-12, IL-23 and TNFα, and high production of IL-10.
These results are consistent with findings reported by
others using similar protocols for DC generation [17,37].
Based on results in experimental models reported by
our laboratory and other groups, involving IL-10- and
TGFβ1-producing DCs in the generation of CD4+CD25+
Foxp3+ regulatory T lymphocytes (Tregs) and IL-10-
secreting type 1 regulatory T cells (Tr1), we can speculate
that MPLA-tDCs could exert a similar regulatory effect
in vivo, favoring the induction and expansion of different
regulatory T cell populations [38-40]. Additionally, it is
well known that IL-10 has an inhibitory effect on IL-12and IL-23 production [41], which could explain the re-
duced levels detected for these cytokines in supernatants
from tDCs and MPLA-tDCs compared to IL-10 levels
measured either with or without CD40L stimulation, thus
favoring the establishment of their tolerogenic phenotype.
These findings are in agreement with those reported by
Harry et al., Anderson et al. and Gárate et al., demonstrat-
ing a low production of pro-inflammatory cytokines in
TolDCs generated with Dex and VitD3, even after CD40
activation [17,20,37]. However, our results for IL-12 and
TNFα production by iDCs and mDCs differ from those
obtained by Anderson et al. [20], who using LPS to acti-
vate DCs and Dex plus vitamin D3 as tolerizing agents,
demonstrated a higher IL-12 and TNFα secretion by iDCs
than that detected in mDCs. In our opinion, these differ-
ences could be explained mainly by variations in the ex-
perimental protocols, including reagents, concentration,
and protocol duration. The stability of the cytokine secre-
tion profile displayed by MPLA-tDCs become evident
after they received the second activation stimulus with
CD40L, since pro-inflammatory cytokines remained lower
than those showed by mDCs. In contrast, IL-10 and
TGFβ1 levels were detected without activation via CD40L
and maintained or even augmented after this strong
stimulation. In addition to the cytokine secretion profiles
provided, DC surface markers expression, evaluated after
24 hours of CD40L stimulation, demonstrated that MPLA-
tDCs are able to maintain a semi-mature phenotype after a
second activation stimulus, confirming their stable pheno-
type. These important features are crucial to be considered
when using cell-based therapies for tolerance recovery in
autoimmunity, given the strong inflammatory environment
that TolDCs will encounter when inoculated.
In order to prevent or reverse progression of auto-
immune diseases, auto-reactive T cells need to be de-
leted or suppressed. In this sense, TolDCs ability to
inhibit or suppress antigen-specific T cell proliferation is
highly desired to induce tolerance. Our study revealed
that tDCs exhibited a weak CD4+ T cell allostimulatory
capacity, even after activation with MPLA, as compared
to mDCs. More important, these CD4+ T cell weak re-
sponses induced by MPLA-tDCs and tDCs in allogeneic
cultures were reproduced in an antigen-specific fashion
using autologous co-cultures, and even more, PPD-loaded
MPLA-tDCs shifted the low IFNγ production profile dis-
played by CD4+ T cells into a robust IL-10 secretion re-
sponse. These observations are in agreement with other
studies demonstrating that Dex-treated DCs exhibit a re-
duced T cell stimulatory capacity either in allogeneic or
antigen-specific co-cultures [23,26,42]. Considering the
MPLA-tDC phenotype, characterized by a high IL-10 and
low IL-12 production, and a reduced costimulatory and
activation machinery, all features related with induction of
regulatory T populations, it still remains to be elucidated
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with tDCs and MPLA-tDCs correspond to induced Tregs
or Tr1 cells [43,44].
As we stated above, TolDCs must maintain their lymph
node-homing capacity mainly through CCR7 expression
in order to be able to migrate to DC-T cell zones and exert
their regulatory effect. Research on semi-mature DCs with
tolerogenic properties and activated with LPS after toler-
ance induction, demonstrated that this feature is essential
for TolDC migratory and antigen presentation capacities
[20]. Since our goal is to generate TolDCs for clinical pur-
poses, we used MPLA for tDCs activation, replacing the
LPS stimulus described for cell activation, and further
evaluated MPLA-tDCs chemokine receptors expression
and the migratory response to their cognate ligands. Ana-
lysis showed that besides CCR7, activated TolDCs also
upregulated CXCR4, another chemokine receptor de-
scribed to be expressed on mature DCs and involved in
DC migration to secondary lymphoid organs [45,46]. Ex-
pression of both chemokine receptors in MPLA-tDCs as
well as in mDCs suggests that these DC types are capable
of migrating to DC-T cell contact sites for antigen presen-
tation, data supported by the results obtained in migration
assays, demonstrating that mDCs and MPLA-tDCs display
migratory abilities in response to CCL19 and CXCL12,
ligands of CCR7 and CXCR4, respectively. On the con-
trary, both mDCs and MPLA-tDCs exhibited a reduced
migratory response to CCL5, ligand of CCR5 and CCR1,
a chemokine related to migration of leukocytes towards
inflamed tissues, while both chemokine receptors were
shown to be upregulated on iDCs [47]. The difference ob-
served in MPLA-tDC migratory response towards CCL19
compared to mDCs, could be related to CCR7 expression
levels determined for each DC type, with mDCs exhibiting
high response towards CCL19, and showing a tendency
to a higher expression of CCR7 compared to MPLA-tDCs.
These results are concordant with those reported by
Anderson et al. [20] using LPS, and with other previous
studies on DCs, showing that MPLA stimulation is enough
to induce tDCs activation and migration, by triggering
a switch in their chemokine receptor expression profile
[45,48,49].
Conclusions
In synthesis, the present study describes a 5-day proto-
col for TolDCs generation using Dex as immunomod-
ulatory agent, and MPLA, a LPS substitute, as tDCs
activator for obtaining clinical grade TolDCs. These
MPLA-tDCs exhibited a semi-mature surface phenotype,
an anti-inflammatory cytokine secretion profile, reduced
allogeneic and antigen-specific CD4+ T cell stimulatory
abilities, and a high expression of chemokine receptors
involved in lymphoid tissue homing. All these features
could validate them to be considered for future clinicalstudies. n addition, our results support the use of TLR-2
as a suitable MPLA-tDC specific marker applicable for
quality control, another desired requirement for clinical
application. This knowledge constitutes an important
step forward in the road to implement new tools for
generating safe and effective TolDCs, which can be used
in therapeutic approaches either in autoimmunity or
transplantation.
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